People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Climate / Cleantech, Other, Investment Vehicle, Other Technology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ChargePoint, Inc. | — | Climate / Cleantech | Series D+ | $570.9M | $3.1B | 2012 |
| Just Fabulous, Inc. | — | Other | Series D+ | $278.4M | $1.8B | 2013 |
| MMAX Investment Partners, Inc. | — | Investment Vehicle | Series B | $96.0M | $480.1M | 2017 |
| Greenfly, Inc. | — | Other Technology | Series A | $45.6M | $55.2M | 2016 |
| Tapjoy, Inc. | — | Other Technology | Series B | $30.1M | $458.3M | 2011 |
| Anacor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $19.4M | $83.6M | 2010 |
| Slacker Inc | — | Other Technology | Series A | $7.0M | $55.1M | 2009 |
| Broadlogic Network Technologies Inc | — | Other Technology | Series A | $4.6M | $126.3M | 2009 |
| Orqis Medical Corp | — | Other Health Care | Seed | $1.2M | $29.6M | 2008 |
Mark Leschly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Leschly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Lee | 1 | 19 |
| Nate Redmond | 1 | 15 |
| Olav B. Bergheim | 1 | 13 |
| David Perry | 1 | 11 |
| Jeffrey Harris | 1 | 9 |
| Louis Toth | 1 | 8 |
| Leo Spiegel | 1 | 8 |
| Brian Dovey | 1 | 7 |
| Mihir Shah | 1 | 7 |
| Paul Klingenstein | 1 | 6 |
| Adam Goldenberg | 1 | 6 |
| Josh Hannah | 1 | 6 |
| Douglas Pepper | 1 | 6 |
| Michael Linse | 1 | 5 |
| Heidi Crane | 1 | 5 |
| Bruce Chizen | 1 | 4 |
| Kenneth Charhut | 1 | 4 |
| Al Schuele | 1 | 4 |
| Daniel Ahn | 1 | 4 |
| Anders Hove | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.